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Available online 11 April 2013Abstract This report brings the first experimental evidence for the presence of long-term (LT) repopulating hematopoietic
stem cells (HSCs) and Side Population (SP) cells within human steady state peripheral blood CD34+ cells. Ex vivo culture, which
reveals the LT-HSC, also increases short-term (ST) HSC engraftment capacity and SP cell number (as well as the SP
subpopulations defined on the basis of CD38, CD90 and CD133 expression) which are very low in freshly isolated cells. Thus, ex
vivo incubation either allows the expansion of the small fraction of HSCs or reveals “Scid Repopulating Cells — SRC” that are
present in the initial CD34+ cell population but unable to engraft. In addition, among these CD34+ cells, we confirm the
presence of committed progenitors at frequencies similar to those found in cord blood CD34+ cells. These cells, obtained from
leukoreduction filters (LRFs) and rejected in the course of the preparation of red blood cell concentrates, are an abundant and
reliable material for obtaining committed progenitors, short- and long-term HSCs of therapeutic interest, especially after the
ex vivo expansion phase. Our results open a perspective to set up new therapeutic protocols using expanded LRFs-recovered
CD34+ cells as a source of HSCs for autologous or allogeneic transplantation.
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The existence of circulating hematopoietic stem cells (HSCs)
in steady state was suggested by the early experiments of
parabiosis in rats (Brecher and Cronkite, 1951) and baboons
(Storb et al., 1977). These observations have been corrobo-
rated by hematopoietic reconstitution of irradiated animals
via injection of steady state peripheral blood cells (Goodman
and Hodgson, 1962; Cavins et al., 1964; Storb et al., 1968;
626 P. Brunet de la Grange et al.Kőrbling et al., 1979). Although several clinical studies in the
80s demonstrated a beneficial effect of autologous (Kőrbling
et al., 1986; Reiffers et al., 1986) and allogeneic (Kessinger et
al., 1989) peripheral blood cell transplantation, the presence
of HSC in human steady state blood was not confirmed by
specific experiments. However, the presence of committed
and multi-lineage progenitors in steady state peripheral blood
has been established both in the animal models and in humans
(McCredie et al., 1971; Chervenick and Boggs, 1971; Barr et
al., 1975; Ivanovic et al., 1997, Ivanovic and Milenkovic,
1999), and these cells have been identified as belonging to the
CD34+ population, whose frequency is very low in steady state
blood (1 to 4 cells/μl) (Bender et al., 1991). Surprisingly, after
a phenomenon called “mobilization” i.e. increase in the
number of committed progenitor cells in blood after chemo-
therapy (Richman et al., 1976) and cytokine treatment
(GM-SCF or G-CSF) (Siena et al., 1990), had been discovered,
the studies on steady state peripheral blood cells were almost
abandoned. Nevertheless, a couple of studies was published
demonstrating the presence of HSC in blood using ex vivo
LTC-IC (Long Term Culture Initiation Cells) (Udomsakdi et al.,
1992) approach and in vivo (SRC; Scid Repopulating Cells)
(Hirayama et al., 2003) approach. Nowadays, it is considered
that the in vivo approach, based on the repopulation of
hematopoietic tissues of immunodeficient mice, enables
estimation of the real HSC capacity. Furthermore, depending
on the approach – analysis of recipient mice several weeks
after injection of human cells, or their bone marrow cell
collection and injection to the secondary recipients which will
be analyzed several weeks afterwards – it is possible to get
insight into two populations of the heterogeneous HSC
compartment: the short- (ST) and long-term (LT) repopulating
hematopoietic stem cells, respectively (reviewed in: Ema,
2010). Importantly, the approach using secondary recipients is
now regarded as a “gold standard” to reveal the LT-HSC.
The present study used described “gold standard”
approach, as well as a complex phenotypic analysis (analysis
of the Side Population — “SP” cells were combined with
CD34, CD38, CD90 and CD133 expression analyses) to
question the presence of primitive HSC in steady state
blood of healthy humans.Material and methods
Recovery of leukocytes and MNC from the LRF
The blood for transfusion purposes is collected only from the
voluntary healthy blood donors. The cells were recovered
from filters (T2975, Fresenius Kabi, Louviers, France) by
counterflow elution as described (Ivanovic et al., 2006a,
2006b). The cells were then centrifuged at low gravity
(10 min at 20 °C, 320 g; Heraeus Multifuge S3, Yutz, France)
to reduce the platelets contamination of the buffy coat. The
platelet rich supernatants were discarded and the buffy
coats containing residual RBC recovered and loaded on Ficoll
(Bicoll separating solution — Biochrom AG, Berlin, Germany).
The MNC fraction was harvested after 20 min of centrifuga-
tion at 290g (Heraeus Multifuge S3, Heraeus Multifuge S3,
Yutz, France), then washed and resuspended in buffer for
the CD34+ isolation. The cells from myeloma patients were
obtained by leukapheresis after the standard mobilizationprotocol (4 g/m2 intravenous (iv) cyclophosphamide followed
by subcutaneous filgrastim (Amgen, Neuilly sur Seine, France;
5 μg/kg/day) until all leukapheresis procedures were col-
lected) (Boiron et al., 2006). The lowest CD34+ cell incidence
before starting leukapheresis procedures was 20/μl for the
series of patients whose results were considered in this study.
Isolation of CD34+ cells
CD34+ cells from MNC fraction issued from LDFs were
isolated by using Miltenyi's (Miltenyi Biotec, Paris, France)
“indirect” immunomagnetic technique (human CD34+ pro-
genitor cell isolation kit “Macs”) (Ivanovic et al., 2006a,
2006b): two passages by using the LS columns (Vario Macs
Device). This approach enabled, in spite of very low starting
concentration of CD34+ cells, relatively good CD34+ purity
(80–98%). CD34+ cells from myeloma patients after mobili-
zation – “Mobilized CD34+ cells” – were selected directly
from leukapheresis products using Isolex 300i (Miltenyi
Biotec, Paris, France) device (Ivanovic et al., 2006b).
Detection of CFU-GM, BFU-E and CFU-Mix
committed progenitors
Freshly isolated CD34+ cells (isolated from LRF or cord blood)
and their progeny after culture were plated in methylcellu-
lose cytokine-supplemented kits (Stem Alpha ID, Saint
Clement les Places, France) and cultured for 14 days in
35 mm Petri dishes (NUNC, Roskilde, Denmark). The colonies
(N50 cells) were then counted (Ivanovic et al., 2006a,
2006b).
Evaluation of ex vivo expansion capacity of
LRF-recovered CD34+ cells
Freshly isolated CD34+ cells were seeded at 20 × 103 cells/ml,
and cultured in 175 cm2 flasks (NUNC, Roskilde, Denmark)
during 7 days in liquid (serum-free medium Macopharma
HP01) cultures supplemented by SCF, G-CSF and MGDF
(100 ng/ml each), IL-3 (0.5 ng/ml) (Ivanovic et al., 2004).
Total cell counting
The cells were counted using automatic cell counter (Cell
Dyn 3000, Abbott, Rungis, France).
CD34+ cell detection and immunophenotypical
analysis
The CD34+ cell concentrations/purities were detected
following the recommendations of the International Society
of Hematotherapy and Graft Engineering (Sutherland et
al., 1996) as previously described (Ivanovic et al., 2006a,
2006b). Briefly, three-color fluorescence was used to detect
viable CD45+/CD34+ cells that were counted directly by a
flow cytometer (FACS Calibur, Becton Dickinson, San Jose,
CA) by using trucount microbeads (Beckton Dickinson, San
Jose, CA). For phenotypic characterization of cultured
cells, the following fluorescein-coupledmonoclonal antibodies
were used: anti-CD13 (PE), anti-CD33 (PE), anti-CD61 (FITC)
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(Pharmingen, San Diego, CA).
Detection of stem cells by their in vivo repopulating
capacity (SRC)
ST-HSC
As described previously (Ivanovic et al., 2011), the animal
experiments were performed in compliance with the French
regulation (License No: 3306002). 200 × 103 CD34+ cells on
Day-0, as well as their whole Day-7 progeny (14,20) were
injected to irradiated (3.5Gy; 60Co source — Gamatron,
Siemens, France) 8–10 week-old NOD/Scid mice (central
animal-keeping facility of Bordeaux Segalen University). In
order to improve the graft efficiency by depleting NK cells,
recipient mice were injected with the anti-CD122 antibody
(produced in our laboratory using the TM-β1 hybridoma
originating from Dr Tanaka laboratory (Tanaka et al., 1991))
24 h prior to the transplantation (100 μg/mice). After 6–
7 weeks, the animals were sacrificed and their femoral
mononuclear bone marrow cells isolated and analyzed by
flow-cytometry (FACS Calibur; Becton Dickinson, San Jose,
CA) for human CD45 (PC7-coupled anti-human antibody,
Immunotech, Marseille, France), CD33 and CD19 (Beckton
Dickinson, San Jose, CA). To avoid false positive results due
to control isotype, we used the non-injected mice to
establish the “positivity threshold” which was 0.5% both for
CD45 and CD33 (Ivanovic et al., 2004, 2011).
LT-HSC
Secondary recipient mice were conditioned as primary
recipients. The bone marrow from both femurs of primary
recipients was flushed out in 1 ml of medium. Apart a 65 μl
aliquot that was used for cell counting and detection of
human CD45 + cells by flow-cytometry, the total cellular
content from both femurs of each primary recipient was
centrifuged, resuspended in 30 μl of RPMI and injected
intrafemorally (Robert-Richard et al., 2006) to the second-
ary recipient NOD/Scid mice. The mice were sacrificed 6–
7 weeks later and the same staining and flow cytometry
analysis as the one for primary recipients were performed on
the bone marrow cells of injected femurs.
Analysis of “Side Population” (SP)
Hoechst low/negative cells, corresponding to cells that
massively exclude the stain, have been designated SP cells
by virtue of their typical flow cytometric profile in Hoechst red
vs. Hoechst blue (Challen and Little, 2006; Johnnidis and
Camargo, 2008). In this cell population HSCs are highly
enriched (Goodell, 2002; Lin and Goodell, 2006; Kim et al.,
2002). More recently, the same procedure based on the use of
a different dye termed DCV (Dye Cycle Violet — DCV) was
described (Telford et al., 2007). DCV allows the delineation of
SP cells displaying the same phenotypic and functional
characteristics as those evidenced with Hoechst (Telford et
al., 2007; She et al., 2008; Mathew et al., 2009). Moreover it
presents the advantage to be analyzed with a UV (350 nm)
laser or violet (405 nm) laser whereas Hoechst strictly requires
the UV one. The optimal conditions for our experimental
set-up were fixed in the preliminary experiments aimed toestablish (i) dose of VDC, (ii) FACS acquisition settings that
depend on the laser used (UV 350 nm or near UV 375 nm
(for Hoechst and VDC) and violet 405 nm (for VDC only)),
(iii) the type of flow cytometer, and (iv) the configura-
tion of filters. The incubation time of 120 min for human
cells was explicitly stated in the publication on the web
site “Goodell lab's protocols”, (http://www.ucl.ac.uk/ich/
services/labservices/FCCF/protocols/goodell_hoechst_sp;
see “other species” section).
In our hands, with this cell type and with our FACS
configuration, 5 μM of VDC was found to be the optimal dose
that gave rise to reproducible data. Freshly isolated or
cultured steady state PB CD34+ cells (5 × 105 cells) were
centrifuged for 10 min at 300 g in washing buffer (HBSS, 2%
FCS, 10 mM Hepes) and resuspended at 106 cells/ml in
reaction medium (DMEM, 2% FCS, 10 mM Hepes and 5 μM
DCV). Cells were incubated with DCV 120 min at 37 °C in a
water bath. As control condition, an aliquot of cells is
incubated in presence of 30 μM of Verapamil in order to
block the ABC transporters and thus abrogate the dye efflux.
The gate for SP was chosen according to Verapamil control
included for each condition of each experiment.
At the end of the incubation, cells were washed in cold
washing buffer for 10 min at 300g, resuspended in 100 μl
of washing buffer for further membrane labeling with
CD34-APCalexa750, CD38-PC7, CD90-APC or CD133-APC. In
each sample, 20 μl of 7-AAD (viability dye) was added.
Cells were incubated on ice for 20 min, then washed in
washing buffer, and resuspended in the same buffer for
flow cytometry analysis. The particular phenotypic subsets
of SP cells in which HSCs were shown to be enriched in
bone marrow and cord blood CD34+ cell population, based
on CD38 (Beckman Coulter), CD133 (Miltenyi Biotech) and
CD90 (BD Pharmingen) expression were evaluated by a
multi-color analysis.Results
Colony forming efficiency of steady state PB CD34+
cells recovered from the LRF
The colony forming efficiency (frequency of committed
progenitors) of steady state PB CD34+ cells is similar to the
one of cord blood CD34+ cells (N = 10) and significantly
higher than that of mobilized CD34+ cells (N = 19) (cumulative
data from our research group obtained using the same culture
system) (Fig. 1A and Ivanovic et al., 2006a).Ex vivo expansion potential of steady state PB
CD34+ cells isolated from LRFs
In serum free cultures supplemented with a cocktail of
cytokines used for ex vivo expansion of CD34+ cells mobilized
in peripheral blood (Ivanovic et al., 2006a), the mean
amplification factor was 25.3 fold, 14.1 fold and 12.5
fold for total cells, CD34+ cells, and CFU, respectively
(Fig. 1B).
Immunophenotype of cells expanded ex vivo from steady
state PB CD34+ cells (Fig. 1C) confirms the capacity of these
cells to generate cells of myeloid (CD13 and CD33) and
Figure 1 Steady state peripheral blood CD34+ cell cloning
efficiency, expansion fold and immunotype of expanded cells.
A. Cloning efficiency given as number of total colony-forming
units (CFU) (CFU-GM + BFU-E + CFU-Mix) per 1000 CD34+ cells
plated. Comparison of steady state peripheral blood CD34+ cells
issued from leukoreduction filters (LRF) (N = 13) with cord blood
CD34+ cells (CB) (N = 10) and CD34+ cells mobilized to peripheral
blood (Mob PB) (N = 19); the data represent means ± SEM.
B. Day-7 expansion fold of total, CD34+ cells and CFU (Plating
efficiency after culture was 207 CFU/1000 cells (440 CFU/1000
CD34+ cells)). The liquid cultures (7 days) (N = 13; each culture
was initiated by CD34+ cell content of 1 LRF) composed of
HP01 medium supplemented with SCF, G-CSF and MGDF
(100 ng/ml each), IL-3 (0.5 ng/ml); the data represent mean ±
SEM. C. Expression of CD34, CD13, CD33, CD41 and CD61 on
cells expanded in cultures described in (B). The data represent
mean ± SD.
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2006b), similar to cord blood CD34+ cells (Ivanovic et al., 2011)
and CD34+ cells mobilized into peripheral blood (Ivanovic
et al., 2006a). An important fraction of cells remained CD34
positive at Day-7 (40%).Immunophenotypic characterization of SP CD34+
cells isolated from LRFs and their ex vivo expansion
progeny
The flow cytometry analysis of freshly isolated steady state
PB CD34+ cells (Day-0) revealed the presence of SP cells in a
low frequency (0.5 ± 0.2%) which persists (0.5 ± 0.1%) after
ex vivo culture (Day-7) (overall population analyzed)
(Fig. 2A). The character of SP population was confirmed by
its disappearance after inhibition of Ca-channels by Verapamil
(Fig. 2B). When only remaining CD34+ cells were analyzed
after culture, the SP frequency was 0.7 ± 0.2% (Fig. 3A). While
on Day-0 all SP cells were CD34+, on Day-7 some SP cells
were identified as CD34− (Fig. 3B). With respect to the
co-expression of CD34 and CD38, all SP cells on Day-0 were
CD34+CD38−/low, whereas after culture only 40% cells of SP
cells maintained CD34+CD38−/low phenotype (Figs. 3B, C).
While the percentage of SP CD34+CD38−/low population positive
for CD90 on Day-0 (21.9 ± 3.1%) decreased on Day-7 (13,8 ±
4.5%) (Fig. 3D), their percentage positive for CD133 (15% on
Day-0) increased after culture (39.2 + 5.5% on Day-7) (Fig. 3E).
In terms of absolute cell number, the total SP CD34+ population
was amplified 21 fold after culture. The amplification of SP
cells expressing the phenotypes considered as “primitive”
was 10, 28 and 5.9 fold for SP CD34+CD38−/low, SP
CD34+CD38−/lowCD90+ and SP CD34+CD38−/lowCD133+ cell
population, respectively (Fig. 3F). Bivariate plots concerning
the quadrant settings delimiting CD38 vs. CD34 subsets in
viable cells of isotype control labeled cells are provided in
Supplementary Fig. 1.HSC with short-term repopulation potential in
CD34+ steady state PB cell population
Application of the same cell dose as the one used for CD34+
cells mobilized in peripheral blood did not result in engraft-
ment of native NOD/Scid mice with steady state PB CD34+
cells. However, the treatment of mice with the anti-CD122
antibody improved the engrafting efficiency: injection of
2 × 105 freshly isolated steady state PB CD34+ cells into
anti-CD122-treated NOD/Scid mice resulted in low engraft-
ment rate: the mean human CD45+ chimerism was 0.8%.
This cell dose yielded both “positive” and “negative” mice
(0.5% threshold) with a maximum CD45 chimerism of 1.1%
(Fig. 4A-i). Similar engraftment rate was obtained for human
CD33 (Fig. 4A-ii) marker. A 24 h culture did not improve
this low engraftment capacity. Interestingly, cells that were
expanded from the same number (2 × 105) of seeded steady
state PB CD34+ cells during 7 days led to human hematopoietic
engraftment of all mice (Figs. 4A-i,ii). Furthermore, about 8
fold (6.3% vs. 0.8%) higher human CD45 (Fig. 4A-i) mean
chimerism level testifies that the 7 day culture of steady state
PB CD34+ cells either revealed a HSC subpopulation unable to
engraft on Day-0 or amplified it.HSC with long-term repopulation potential in CD34+
steady state PB cell population
The presence of LT-HSC in steady state CD34+ cell population
recovered from the LRFs was revealed by the capacity of
Figure 2 Side Population (SP) in overall cell population. Day-0: fresh CD34+ cells isolated from LRFs; Day-7: total cells generated
from Day-0 CD34+ cells after 7 days in culture. Side population in frame (black dots). Note that both in Day-0 and Day-7 samples
incubation with Verapamil results in disappearing of SP.
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secondary NOD/Scid recipient mice. These experiments were
performed only with the cultured cells since the enhanced
ST-HSC activity by ex vivo culture pointed to their potential
interest for cell therapy. Thus, as expected, injection of Day-7
culture progeny of 1 × 106 steady state CD34+ cells resulted
6 to 7 weeks later in high human chimerism in primary
recipients for the tested markers (Figs. 4B-i,ii). When the
bone marrow cells of primary recipients were injected in
femur of secondary recipient, human hematopoietic chime-
rism was clearly detectable in 8/10 of mice 6 to 7 weeks after
injection, (Figs. 4B-i,ii). These results indicate that the very
primitive stem cells (LT-HSC) are present among steady state
blood CD34+ cells.Discussion
The presence in the graft products of HSC exhibiting capacity
of life-long hematopoietic reconstitution is mandatory for
clinical transplantation. The secondary engraftment of immu-
nodeficient mice by human hematopoietic cells issued from
primary xenografted mice is presently the “gold standard”
for testing LT-HSC. Recently, we successfully employed this
method to test the graft potential of cord blood steady state
as well as ex vivo amplified cells (Ivanovic et al., 2011). Thesedata are very likely to be relevant for engraftment in humans,
taking into account that the maintenance of LT-HSC xenograft
capacity after the ex vivo expansion of cord blood CD34+ cells
(Ivanovic et al., 2011) is consistentwith the ability of a graft to
provide the long-term hematopoietic reconstitution of
transplanted patients (Milpied et al., 2011).
The results of this study clearly demonstrate the
presence of very primitive HSCs (LT-HSC) in steady state
blood CD34+ cells which were not lost in course of the ex vivo
culture. This experimental evidence that LT-HSCs are
present in human blood in steady state is in line with recent
findings of Utter et al. (2008) of persisting microchimerism
of donor type in war veterans who received transfusion(s) of
non-leukodepleted blood several decades ago.
Concerning the ST-HSC, our results, demonstrating a low
ability to engraft primary recipients of SRC on Day-0 and
Day-1, are in line with those of Hirayama et al. (2003) who
found similar proportion of engrafted mice and chimerism
with steady state CD34+ cells after 4 h of incubation at
37 °C.
Our results that reveal the presence of LT-HSC in steady
state PB can provide the “missing piece of the puzzle”
showing that all stages of hematopoietic stem cells circulate
in steady state blood of healthy persons. Furthermore, all
these cells, trapped together on LRFs, could be easily eluted
for use (Ivanovic et al., 2006a, 2006b; Peytour et al., 2010).
Figure 3 Immunophenotype of CD34+ SP cells at Day-0 and Day-7. (A) SP in CD34+ cell Population; (B) Distribution of SP (black dots)
with respect to expression of CD34 and CD38 in total cell population. C. Windows “covering” CD34+CD38−/low cells that were analyzed on
CD90 (D) and CD133 expression (E). F. Total number of SP, SP CD34+CD38−/low, SP CD34+CD38−/lowCD133+ and SP CD34+CD38−/lowCD90+
cells per culture (5 ml) on Day-0 and Day-7. The factor of amplification on the top of bars.
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leukoreduction, frequently applied and even mandatory in
some countries (France, for example), produces a huge
quantity of cell-saturated filters, which are actually destroyed
as a medical waste. If one takes into consideration the real
possibility to cryopreserve the cells issued from several filters
of the same donor collected during a long period (several
donations per year), the potential clinical value of these
steady state PB cells becomes self-evident. Themajor interest
in this source of HSC is further strengthened both by the fact
that the ex vivo expansion of the hematopoietic stem and
progenitor cells from CD34+ cells is proving its clinical utility
(Reiffers et al., 1999; Boiron et al., 2006; Milpied et al., 2011),
and our data that show dramatic improvement of the HSC
engraftment capacity of these steady state PB CD34+ cells by
the ex vivo culture. The 8 fold enhancement of ST-HSC activity
after 7 days of culture could result either from numerical
amplification of SRC during the expansion culture or/and from
an improvement of their homing/seeding in recipient's bone
marrow niches, which remains to be elucidated in further
studies. It is important to mention that this enhancement in
HSC activity in the course of culture is paralleled by the 12.5fold amplification of committed progenitors (14 fold of CD34+
cells). Indeed, the committed progenitor content in an ex vivo
expanded hematopoietic graft appears to be a determining
factor for the shortening of neutropenia period and related
infectious risks after hematopoietic transplantation in pa-
tients (Milpied et al., 2011; Utter et al., 2008; Reiffers et al.,
1999; Boiron et al., 2006).
The expression of chemokines, adhesive molecules, cyto-
kine receptors and other markers was extensively studied on
PB steady state CD34+ cells (Lataillade et al., 2005). However,
one cannot assume that the expression of these molecules at
the surface of the total CD34+ cell population is strictly
relevant to stem cells, especially after the ex vivo culture
(Danet et al., 2001), since CD34+ cell population is function-
ally heterogeneous and contains a minority of the stem
cells. Furthermore, primitive stem cells are identified on the
basis of their capacity to repopulate secondary recipients
(thus indirectly) and remain phenotypically “elusive” due
to their very low frequency and the fact that the known
immunophenotype markers do not seem to be specifically
related to the stem cell potential and function. Nevertheless,
HSCs are enriched in some phenotypically-defined CD34+
Figure 4 Short- and long-term repopulating stem cells in steady state peripheral blood CD34+ population: (A) Human CD45 (i) and
CD33 (ii) chimerism (percentages of human cells among femoral cells) in primary recipients injected either with 2 × 105 freshly
harvested (Day-0) CD34+ cells or with their whole progeny after 1 (Day-1) and 7 days (Day-7) of culture. Two to 3 mice per condition
were analyzed (6–7 weeks after injection of cells) in 3 independent experiments; on the graphs, each point represents one mouse and
the horizontal black bars the median values. Each experiment was performed with CD34+ cells extracted and pooled from 4–8 LRFs.
**p b 0.01; ***p b 0.001. (B) Human CD45 (i) and CD33 (ii) chimerism (percentages of human cells in the femoral cells suspension)
after primary and secondary graft of the 7 day progeny of 1 × 106 CD34+ cells seeded on Day-0. Three to 5 mice per condition were
analyzed in 3 independent experiments; on the graphs, each point represents one mouse and the horizontal black bars the median
values. Each experiment was performed with CD34+ cells extracted and pooled from 12 LRFs.
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defined initially on a very restrained subset of murine and
human bone marrow and human cord blood cells on the basis
of the activity of a membrane calcium-dependent pump (“ABC
transporters”) capable to reject somemolecules from the cell
(Kim et al., 2002). We present here the first data demonstrat-
ing that such a population of cells exists in the steady state
human blood and is numerically enhanced after the ex vivo
culture (Fig. 3F). We detected the SP frequency 0.5% to 0.7%
which is consistent with the data published for the CD34+
(CD34+38−) populations originating from: peripheral blood
after mobilization (Josefsen et al., 2011) human fetal and
adult liver (Uchida et al., 2001; Pierre-Louis et al., 2009) and
other tissues (Asakura and Rudnicki, 2002).These findings are consistent with a low SRC activity
which is increased after ex vivo culture (Fig. 4A). In a parallel
project, we found that CD34+CD38−/low and not CD34+CD38+
fraction of cultured steady state PB cells contains the cells
exhibiting the capacity to engraft NSG mice (giving human
CD45+, CD33+ (myeloid) and CD19+ (lymphoid) cells in murine
bone marrow) (work in progress). Thus, the SP cells were
analyzed with respect to CD38 expression (Figs. 3B, C). Taking
into account only CD34+CD38−/low SP cells, the phenomenon of
increase in absolute cell number after culture persists (10
fold) (Fig. 3F), which is similar to the increase in SRC activity in
the same condition (human chimerism increased about 8 fold),
suggesting that the HSCs are really highly enriched in this SP
CD34+CD38−/low cell fraction. In line with this observation are
632 P. Brunet de la Grange et al.also our results showing a numerical increase in CD90+ (5.9
fold) and CD133+ (28 fold) subpopulations of SP CD34+CD38−/low
cells.
We can thus conclude that the CD34+ cells purified
from LRF steady state PB contain a restricted population of
short- and long-term repopulating HSC, a finding completely
consistent with the one of a low-frequency SP and SP
CD34+CD38−/low populations (as well as its CD90+ and CD133+
subpopulations). These populations increase after culture as
does the SRC activity.
We envision that these results should encourage new R&D
projects devoted to the therapeutic use of steady state PB
cells issued from LRF as a source of autologous or allogeneic
HSC to be expanded before their reinjection to patients.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.04.003.
Acknowledgments
The authors are thankful to Mrs Elisabeth Doutreloux-
Volkmann and Dr Ivana Gadjanski for the language correc-
tions. This project was supported by the grant “EFS Recherche
2011 No 2011-07”.
References
Asakura, A., Rudnicki, M.A., 2002. Side population cells from diverse
adult tissues are capable of in vitro hematopoietic differentiation.
Exp. Hematol. 30, 1339–1345.
Barr, R.D., Whang-Peng, J., Perry, S., 1975. Hemopoietic stem cells
in human peripheral blood. Science 190, 284–285.
Bender, J.G., Unverzagt, K.L., Walker, D.E., Lee, W., Van Epps,
D.E., Smith, D.H., Stewart, C.C., To, L.B., 1991. Identification
and comparison of CD34-positive cells and their subpopulations
from normal peripheral blood and bone marrow using multicolor
flow cytometry. Blood 77, 2591–2596.
Boiron, J.M., Dazey, B., Cailliot, C., Launay, B., Attal, M., Mazurier,
F., McNiece, I.K., Ivanovic, Z., Caraux, J., Marit, G., Reiffers, J.,
2006. Large-scale expansion and transplantation of CD34(+)
hematopoietic cells: in vitro and in vivo confirmation of
neutropenia abrogation related to the expansion process without
impairment of the long-term engraftment capacity. Transfusion
46, 1934–1942.
Brecher, G., Cronkite, E.P., 1951. Post-irradiation parabiosis and
survival in rats. Proc. Soc. Exp. Biol. Med. 77, 292–294.
Cavins, J.A., Scheer, S.C., Thomas, E.D., 1964. The recovery of
lethally irradiated dogs given infusions of autologous leukocytes
preserved at −80 °C. Blood 23, 38–43.
Challen, G.A., Little, M.H., 2006. A side order of stem cells: the SP
phenotype. Stem Cells 24, 3–12.
Chervenick, P.A., Boggs, D.R., 1971. In vitro growth of granulocytic
and mononuclear cell colonies from blood of normal individuals.
Blood 37, 131–135.
Danet, G.H., Lee, H.W., Luongo, J.L., Simon, M.C., Bonnet, D.A.,
2001. Dissociation between stem cell phenotype and NOD/SCID
repopulating activity in human peripheral blood CD34(+) cells
after ex vivo expansion. Exp. Hematol. 29, 1465–1473.
Ema, H., 2010. In vivo and in vitro essays for HSCs. In: Kondo,
Motonori (Ed.), Hematopoietic Stem Cells Biology. Humana
Press, Springer, New York, pp. 6–110.
Goodell, M.A., 2002. Multipotential stem cells and ‘side population’
cells. Cytotherapy 4, 507–518.
Goodman, J.W., Hodgson, G.S., 1962. Evidence for stem cells in the
peripheral blood of mice. Blood 19, 702–714.Hirayama, F., Yamaguchi, M., Yano, M., Yasui, K., Horie, Y.,
Matsumoto, K., Nagao, N., Ikebuchi, K., Azuma, H., Ikeda, H.,
Tani, Y., 2003. Spontaneous and rapid reexpression of functional
CXCR4 by human steady-state peripheral blood CD34+ cells. Int.
J. Hematol. 78, 48–55.
Ivanovic, Z., Milenkovic, P., 1999. Pluripotent haemopoietic
progenitor cells (CFU-Sd8) in peripheral blood of hereditarily
anaemic Belgrade (b/b) rats. Lab. Anim. 33, 77–82.
Ivanovic, Z., Petakov, M., Jovcic, G., Biljanovic-Paunovic, L., Balint,
B., Milenkovic, P., 1997. Pluripotent and committed haemopoietic
progenitor cells in rat peripheral blood. Comp. Haematol. Int. 7,
1–6.
Ivanovic, Z., Hermitte, F., Brunet de la Grange, P., Dazey, B., Belloc,
F., Lacombe, F., Vezon, G., Praloran, V., 2004. Simultaneous
maintenance of human cord blood SCID-repopulating cells and
expansion of committed progenitors at low O2 concentration (3%).
Stem Cells 22, 716–724.
Ivanovic, Z., Duchez, P., Morgan, A.D., Hermitte, F., Lafarge, X.,
Chevaleyre, J., Praloran, V., Dazey, B., Vezon, G., Boiron, J.M.,
2006a. Whole blood leukodepletion filters as a source of CD34+
progrenitors potentially usable in cell therapy. Transfusion 46,
118–125.
Ivanovic, Z., Duchez, P., Dazey, B., Hermitte, F., Lamrissi-Garcia,
I., Mazurier, F., Praloran, V., Reiffers, J., Vezon, G., Boiron,
J.M., 2006b. A clinical-scale expansion of mobilized CD34+
haematopoietic stem and progenitor cells by use of a new serum-
free medium. Transfusion 46, 126–131.
Ivanovic, Z., Duchez, P., Chevaleyre, J., Vlaski, M., Lafarge, X.,
Dazey, B., Robert-Richard, E., Mazurier, F., Boiron, J.M., 2011.
Clinical-scale cultures of cord blood CD34+ cells to amplify
committed progenitors and maintain stem cell activity. Cell
Transplant. 20, 1453–1463.
Johnnidis, J.B., Camargo, F.D., 2008. Isolation and functional
characterization of side population stem cells. Methods Mol. Biol.
430, 183–193.
Josefsen, D., Forfang, L., Dyrhaug, M., Blystad, A.K., Stokke, T.,
Smeland, E.B., Kvalheim, G., 2011. Side population cells in
highly enriched CD34-poitive cells from peripheral blood pro-
genitor cells identify an immature subtype of hematopoietic
progenitor cells but do not predict time to engraftment in
patients treated with high-dose therapy. Eur. J. Haematol. 87,
494–502.
Kessinger, A., Smith, D.M., Strandjourd, S.E., Landmark, J.D., Dooley,
D.C., Law, P., Coccia, P.F., Warkentin, P.I., Weisenburger, D.D.,
Armitage, J.O., 1989. Allogenic transplantation of blood-derived,
T cell-depleted hemopoietic stem cells after myeloablative
treatment in a patient with acute lymphoblastic leukaemia. Bone
Marrow Transplant. 4, 643–646.
Kim, M., Turnquist, H., Jackson, J., Sgagias, M., Yan, Y., Gong, M.,
Dean, M., Sharp, J.G., Cowan, K., 2002. The multidrug resistance
transporter ABCG2 (breast cancer resistance protein 1) effluxes
Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Clin. Cancer Res. 8, 22–28.
Kőrbling, M., Fliedner, T.M., Calvo, W., Ross, W.M., Nothdurft, W.,
Steinbach, I., 1979. Albumin density gradient purification of
canine hemopoietic blood stem cells (HBSC): long-term allogenic
engraftment without GVH-reaction. Exp. Hematol. 7, 277–288.
Kőrbling, M., Dorken, B., Ho, A.D., Pezzuto, A., Hunstein, W., Fliedner,
T.M., 1986. Autologous transplantation of blood-derived hemopoi-
etic stem cells after myeloablative therapy in a patient with
Burkitt's lymphoma. Blood 67, 529–532.
Lataillade, J.J., Clay, D., David, C., Boutin, L., Guerton, B., Drouet,
M., Hérodin, F., Le Bousse-Kerdilès, M.C., 2005. Phenotypic and
functional characteristics of CD34+ cells are related to their
anatomical environment: is their versatility a prerequisite for
their bio-availability? J. Leukoc. Biol. 77, 634–643.
Lin, K.K., Goodell, M.A., 2006. Purification of hematopoietic stem
cells using the side population. Methods Enzymol. 420, 255–264.
633Long-term hematopoietic stem cells and “side population” in human steady state peripheral bloodMathew, G., Timm Jr., E.A., Sotomayor, P., Godoy, A., Montecinos,
V.P., Smith, G.J., Huss, W.J., 2009. ABCG2-mediated Dye Cycle
Violet efflux defined side population in benign and malignant
prostate. Cell Cycle 8, 1053–1061.
McCredie, K.B., Hersh, E.M., Freireich, E.J., 1971. Cells capable of
colony formation in the peripheral blood of man. Science 171,
293–294.
Milpied, N., Dazey, B., Ivanovic, Z., Duchez, P., Vigouroux, S., Tabrizi,
R., Pigneux, A., Dilhuydy, M.S., Bouabdallah, K., Leguay, T.,
Sauvezie, M., Boiron, J.M., 2011. Rapid and sustained engraftment
of a single allogeneic ex-vivo expanded cord blood unit (CBU) after
reduced intensity conditioning (RIC) in adults: preliminary results
of a prospective trial. ASH Congress, San Diego, USA. Abstract 226
Blood 118 (21), 226.
Peytour, Y., Guitart, A., Villacreces, A., Chevaleyre, J., Lacombe,
F., Ivanovic, Z., Praloran, V., 2010. Obtaining of CD34+ cells
from healthy blood donors: development of a rapid and efficient
procedure using leukoreduction filters. Transfusion 50, 2152–2157.
Pierre-Louis, O., Clay, D., Brunet de la Grange, P., Blazsek, I.,
Desterke, C., Guerton, B., Blondeau, C., Malfuson, J.V., Prat,
M., Bennaceur-Griscelli, A., Lataillade, J.J., Le Bousse-Kerdilès,
M.C., 2009. Dual SP/ALDH functionalities refine the human
hematopoietic Lin-CD34 + CD34-stem/progenitor cell compart-
ment. Stem Cells 27, 2552–2562.
Reiffers, J., Bernard, P., David, B., Vezon, G., Sarrat, A., Marit, G.,
Moulinier, J., Broustet, A., 1986. Successful autologous trans-
plantation with peripheral blood hemopoietic cells in a patient
with acute leukaemia. Exp. Hematol. 14, 312–315.
Reiffers, J., Cailliot, C., Dazey, B., Attal, M., Caraux, J., Boiron,
J.M., 1999. Abrogation of post-myeloablative chemotherapy
neutropenia by ex-vivo expanded autologous CD34-positive cells.
Lancet 354, 1092–1093.
Richman, C.M., Weiner, R.S., Yankee, R.A., 1976. Increase in
circulating stem cells following chemotherapy in man. Blood 47,
1031–1039.
Robert-Richard, E., Ged, C., Ortet, J., Santarelli, X., Lamrissi-Garcia,
I., de Verneuil, H., Mazurier, F., 2006. Human cell engraftment
after busulfan or irradiation conditioning of NOD/SCID mice.
Haematologica 91, 1384–1387.She, J.J., Zhang, P.G., Wang, Z.M., Gan, W.M., Che, X.M., 2008.
Identification of side population cells from bladder cancer cells
by Dye Cycle Violet staining. Cancer Biol. Ther. 7, 1663–1668.
Siena, S., Bregni, M., Ravagnani, F., Brando, B., Tarella, C.,
Bonadonna, G., Gianni, A.M., 1990. Heterogeneity of circulating
hematopoietic progenitors in cancer patients treated with high-
dose cyclophosphamide and recombinant human granulocyte
macrophage colony stimulating factor (rhGM-CSF). Haematologica
75 (Suppl. 1), 6–10.
Storb, R., Epstein, R.B., Thomas, E.D., 1968. Marrow repopulating
ability of peripheral blood cells compared to thoracic duct cells.
Blood 50, 537–542.
Storb, R., Graham, T.C., Epstein, R.B., Sale, G.E., Thomas, E.D.,
1977. Demonstration of hemopoietic stem cells in the peripheral
blood of baboons by cross circulation. Blood 50, 537–542.
Sutherland, D.R., Anderson, L., Keeney, M., Nayar, R., Chin-Yee, I.,
1996. The ISHAGE guidelines for CD34+ cell determination by
flow cytometry. International Society of Hematotherapy and
Graft Engineering. J. Hematother. 5, 213–226.
Tanaka, T., Tsudo, M., Karasuyama, H., Kitamura, F., Kono, T.,
Hatakeyama, M., Taniguchi, T., Miyasaka, M., 1991. A novel
monoclonal antibody against murine IL-2 receptor beta-chain.
Characterization of receptor expression in normal lymphoid cells
and EL-4 cells. J. Immunol. 147, 2222–2228.
Telford, W.G., Bradford, J., Godfrey, W., Robey, R.W., Bates, S.E.,
2007. Side population analysis using a violet-excited cell-
permeable DNA binding dye. Stem Cells 25, 1029–1036.
Uchida, N., Fujisaki, T., Eaves, A.C., Eaves, C.J., 2001. Trans-
plantable hematopoietic stem cells in human fetal liver have a
CD34+ side population (SP) phenotype. J. Clin. Invest. 1058,
1071–1077.
Udomsakdi, C., Lansdorp, P.M., Hoggs, D.E., Reid, D.C., Eaves, A.C.,
Eaves, C.J., 1992. Characteristic of primitive hematopoietic cells
in normal human peripheral blood. Blood 80, 2513–2521.
Utter, G.H., Lee, T.H., Rivers, R.M., Montalvo, L., Wen, L., Chafets,
D.M., Reed, W.F., Busch, M.P., 2008. Microchimerism decades
after transfusion among combat-injured US veterans from the
Vietnam, Korean, and World War II conflicts. Transfusion 48,
1609–1615.
